The University of Chicago Header Logo

Connection

Michael Becker to Drug Resistance

This is a "connection" page, showing publications Michael Becker has written about Drug Resistance.
Connection Strength

0.213
  1. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis. 2013 Sep 01; 72(9):1469-74.
    View in: PubMed
    Score: 0.101
  2. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014 Dec; 20(8):427-32.
    View in: PubMed
    Score: 0.029
  3. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther. 2013 Sep 26; 15(5):R137.
    View in: PubMed
    Score: 0.027
  4. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA. 2011 Aug 17; 306(7):711-20.
    View in: PubMed
    Score: 0.023
  5. Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease. Am J Hematol. 2011 Aug; 86(8):712-4.
    View in: PubMed
    Score: 0.023
  6. Diminished affinity for purine substrates as a basis for gout with mild deficiency of hypoxanthine-guanine phosphoribosyltransferase. Adv Exp Med Biol. 1977; 76A:319-25.
    View in: PubMed
    Score: 0.008
  7. Purine metabolism in normal and thioguanine-resistant neuroblastoma. Proc Natl Acad Sci U S A. 1973 Dec; 70(12):3880-3.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.